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Unprecedented reductive cyclisation of salophen ligands to 
tetrahydroquinoxalines during metal complex formation 
Katie J. Lamb,a Mark R. Dowsett,b Michael North,*a Rachel R. Parkerb and Adrian C. Whitwoodb 
The synthesis of novel tetrahydroquinoxalines by a metal induced 
one–electron reductive cyclisation of salophen ligands was found 
to occur when a salophen ligand was treated with chromium(II) 
chloride or decamethylcobaltocene. 
Salen and salophen ligands (Figure 1) are very commonly 
utilised privileged ligands which readily form mono- and/or 
poly-metallic complexes with just about any metal in the 
periodic table.1 The resulting metal complexes have a wide 
range of catalytic2 and other3 applications. For example; chiral 
manganese(salen) complexes catalyse the asymmetric 
epoxidation of alkenes, cobalt(salen) complexes catalyse the 
ring–opening of epoxides, chiral salen complexes of titanium 
and vanadium catalyse asymmetric cyanohydrin synthesis and 
salen and salophen complexes of aluminium catalyse the 
synthesis of cyclic carbonates and oxazolidinones from carbon 
dioxide and epoxides or aziridines.4,5
Salen and salophen complexes of chromium are also very 
well-known and widely used catalysts6 and we have 
investigated the use of chromium(III)(salophen) complexes as 
catalysts for cyclic carbonate synthesis from carbon dioxide 
and both terminal and internal epoxides.7 In the course of this 
work we encountered a previously unknown side reaction 
which complicates the usual preparation of 
chromium(salophen) complexes by treatment of a salophen 
ligand with chromium(II) chloride followed by oxidation using 
atmospheric oxygen. In this paper we report this side reaction 











Figure 1: General structures of salen and salophen ligands. Substituents can also be 




1. CrCl2 (2 equiv.), Ar, 24 h, dry THF, 25
oC, then air, 24 h

































a: R1=tBu; R2=H; R3=OMe; R4=H
b: R1=H; R2=H; R3=H; R4=H
c: R1=H; R2=H; R3=tBu; R4=H
d: R1=H; R2=OMe; R3=H; R4=H
e: R1=H; R2=H; R3=OMe; R4=H
f: R1=H; R2=H; R3=H; R4=OMe
g: R1=H; R2=OMe; R3=H; R4=OMe
h: R1=H; R2=H; R3=CF3; R
4=H
Scheme 1. Synthesis of chromium(III)(salophen) complexes 2a–h and trans-
tetrahydroquinoxalines 3a–h
Treatment of salophen ligand 1a with chromium(II) 
chloride gave, in addition to the expected 
chromium(III)(salophen) chloride complex 2a, an unexpected 
side product (Scheme 1). The side product could be isolated in 
5% yield as white crystals by column chromatography and its 
structure was determined to be tetrahydroquinoxaline 3a by 
X-ray crystallography (Figure 2).‡ A key feature of the crystal 
structure is the presence of two intramolecular hydrogen 
bonds which result in the formation of a conformation in 
which the two phenol rings are approximately orthogonal to 
the plane of the tetrahydroquinoxaline. As a consequence, the 
hydrogens at position R4 are each located under the centre of 
the other phenol ring.
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Figure 2: ORTEP plot of tetrahydroquinoxaline 3a. Hydrogen atoms have been 
omitted for clarity and ellipsoids are shown at 50% probability.
The proton NMR spectrum of compound 3a in deuterated 
chloroform suggested that the same conformation was 
adopted in chloroform solution as the signal for the hydrogen 
at position R4 was found to occur at 5.75 ppm consistent with 
it being shielded due to its location within the sphere of 
influence associated with the ring current of the other phenol 
ring.8 This signal was also found not to be temperature 
dependent between 218 and 328 K, suggesting that the proton 
at position R4 is unable to move out of the sphere of influence 
associated with the ring current of the other phenol ring 
throughout this temperature range. This implies that there is 
no rotation around the CH-phenol bonds and hence that the 
intramolecular hydrogen bonds are maintained throughout 
this temperature range.
The formation of tetrahydroquinoxaline 3a can be 
explained by the mechanism shown in Scheme 2. Chromium(II) 
chloride can act as a one electron reductant, forming a highly 
delocalised radical anion, one resonance form of which is 
represented by structure 4. There is literature precedent for 
the formation of radical anions from salen and salophen 
complexes.9 Radical anion 4 can then undergo a favourable 6-
endo-trig ring closure10 followed by proton transfer from a 
phenol to give cyclised radical 5. A second chromium(II) 
chloride can then reduce radical 5 to the corresponding anion; 
which, after proton transfer from the other phenol, would give 
bis-phenoxide 6. Protonation of compound 6 during work-up 
gives tetrahydroquinoxaline 3a. To confirm that compound 3a 
was formed during the formation of salophen complex 2a and 
not as a decomposition product of 2a during its crystallisation, 
a batch of 2a was prepared and the unpurified reaction 
mixture analysed by high resolution mass spectrometry which 
showed the presence of both 2a and 3a. Formation of 
tetrahydroquinoxaline 3a also occurred, in 5% yield, when 
stirring under air for 24 hours was omitted from the synthetic 
procedure (Scheme 1, conditions 2). A control experiment in 
which salophen ligand 1a was stirred under argon in THF, in 
the absence of chromium(II) chloride, led only to the recovery 
of starting material. Treatment of salen ligand (Figure 1, 
R1=R2=H) with chromium(II) chloride led only to the 
corresponding chromium(salen) complex, consistent with 
formation of a highly delocalised radical anion intermediate 





















































Scheme 2: Proposed mechanism for the formation of tetrahydroquinoxaline 3a.
Table 1: Substrate Scope
Entry Product R1 R2 R3 R4 Yield (%)a
1 3a tBu H OMe H 5
2 3b H H H H 8
3 3c H H tBu H 8
4 3d H OMe H H 12
5 3e H H OMe H 5
6 3f H H H OMe 12
7 3g H OMe H OMe 2
8 3h H H CF3 H 12
9b 3a tBu H OMe H 10
10b 3b H H H H 15
a) Isolated yields after purification by column chromatography; b) Using 
decamethylcobaltocene as the reducing agent.
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To investigate the generality of this tetrahydroquinoxaline 
synthesis, eight salophen ligands (1a–h), with different 
electronic and steric properties were reacted with 
chromium(II) chloride under conditions 2 used for the 
synthesis of 3a (Scheme 1). In each case the corresponding 
trans-tetrahydroquinoxaline  3a–h  was  isolated  in  yields  of  
2–15% after column chromatography.
Crystals of four additional tetrahydroquinoxalines (3b,c,f,h) 
were grown and analysed by X-ray crystallography.‡ In each 
case the X-ray structures confirmed the trans-orientation of 
the phenolic rings and showed the same hydrogen bond 
stabilised conformation as for compound 3a (Figure 2). The 
intramolecular hydrogen bonds in these structures all had 
lengths of 1.80–2.08Å and donor–acceptor distances of 2.65–
2.78 Å which are consistent with the formation of moderate 
intramolecular hydrogen bonds.11 There is no apparent trend 
in the yield of compounds 3a–h as the electronic properties of 
the salophen ligands were varied. In particular, entries 4, 6 and 
8 of Table 1 all gave the same yield of tetrahydroquinoxaline 3 
even though two of the substrates (2d,f) possess electron-
donating methoxy groups on their phenol rings whilst the 
phenol rings of salophen 2h are substituted with electron 
withdrawing trifluoromethyl groups. Similarly, there appears 
to be no influence of sterically demanding tert-butyl groups on 
the salophen ligands (compare entries 1 and 5 and entries 2 
and 3). The formation of tetrahydroquinoxaline 3g was 
particularly low (Table 1, entry 7), which can be attributed to 
stability issues as the isolated product slowly decomposed 
over time. 
To investigate the importance of the chromium in 
tetrahydroquinoxaline formation, electron rich and electron 
neutral salophen ligands (1a and 1b respectively), were 
reacted with cobalt(II) chloride instead of chromium(II) 
chloride under otherwise identical reaction conditions 
(Scheme 1, conditions 2). No formation of 
tetrahydroquinoxalines 3a,b was detected by mass 
spectrometry or NMR analysis of the unpurified reaction 
mixtures. Therefore, a range of one–electron reducing agents 
with different redox potentials were screened under the same 
reaction conditions. The reducing agents used were: 
decamethylcobaltocene,12 decamethylferrocene,13 titanocene 
dichloride,14 samarium(II) iodide15 and tetrathiafulvene.16 
When screened with salophen ligands 1a,b, only 
decamethylcobaltocene led to the formation of 
tetrahydroquinoxalines 3a,b, in 10% and 15% yield 
respectively (Table 1, entries 9 and 10). These yields are 
approximately double those obtained using chromium(II) 
chloride which could be attributed both to the difference in 
reducing potential of the chromium(II)and cobalt(II) species 
and to the inability of decamethylcobaltocene to act as a 
cobalt source for the formation of a cobalt(salophen) complex. 
The formation of tetrahydroquinoxalines 3a,b from ligands 
1a,b upon treatment with decamethylcobaltocene proves that 
the reaction does not occur via a chromium(salophen) 
complex and so must involve cyclisation of the free ligand.  
Literature data12,14,17 suggested that 
decamethylcobaltocene was the strongest of these reducing 
Table 2: Reduction potentials (E1/2) relative to a standard hydrogen electrode (SHE)
One-electron reductant E1/2a E1/2 (lit)b
decamethylcobaltocene -1.50 -1.5417
samarium(II) iodide -1.31 -1.5518
titanocene dichloride -0.94 -0.8114
chromium(II) chloride -0.40 -0.4118
decamethylferrocene -0.16 -0.1917
2a +0.65 and +0.92 na
a) Measured in dry THF under a nitrogen atmosphere vs a Pt reference electrode. 
Values were converted to vs SHE (see supporting information); b) Measured 
under standard electrochemical conditions in aqueous solution. 
agents under standard aqueous electrochemical conditions. To 
confirm that this was also the case under the anhydrous 
reaction conditions used for the synthesis of 
tetrahydroquinoxalines, cyclic voltammetry14 of all the 
potential reductants was carried out in anhydrous THF under a 
nitrogen atmosphere and this confirmed that 
decamethylcobaltocene was strongest reducing agent under 
the reaction conditions (Table 2). However, the nature of the 
reductant (for example its solubility and stability under the 
reaction conditions) and the relative rates associated with its 
ability to act as a reductant and to form a metal(salophen) 
complex must also have an influence on the reductive 
cyclisation. This is shown by samarium(II) iodide and 
titanocene dichloride which have reduction potentials 
between those of  decamethylcobaltocene and chromium(II) 
chloride and so would be expected to be capable of forming 
tetrahydroquinoxalines 3, but failed to do so.
Cyclic voltammetry was also used to investigate whether 
the reducing agent involved in reactions carried out in the 
presence of chromium(II) chloride was chromium(II) chloride 
itself or the chromium(II)(salophen) complex formed in situ 
from chromium(II) chloride and ligand 1a. Comparison of the 
cyclic voltammograms of chromium(II) chloride and complex 
2a showed that the chromium(II)(salophen) complex (formed 
by electrochemical reduction of complex 2a within the cyclic 
voltammetry experiment) is a much weaker reducing agent 
than chromium(II) chloride. As expected, the cyclic 
voltammogram of complex 2a did show two reversible, one-
electron redox processes, due to sequential oxidation of the 
phenolates as previously reported for other salen and 
salophen complexes.19 This rules out mechanistic pathways 
which involve a chromium(II)(salophen) species acting as a 
reducing agent for an uncomplexed salen ligand or the 
complexed chromium acting as a one–electron reductant for 
its own salophen ligand to give a chromium(III) complex of the 
radical anion of a salophen ligand. 
Conclusion
This work has shown that the synthesis of metal(salophen) 
complexes from a salophen ligand and a metal salt is not 
always as clean a reaction as is generally assumed. Care should 
be taken to purify the resulting metal(salophen) complexes 
prior to their use as catalysts, especially when the metal is 
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capable of undergoing redox reactions to avoid misleading 
results.
The synthesis of tetrahydroquinoxalines by reductive 
cyclisation of salophen ligands represents a new and highly 
stereocontrolled approach to the synthesis of this heterocyclic 
ring system which is found in many bioactive molecules 
including: cholesteryl ester transfer protein inhibitors, 
prostaglandin D2 receptor antagonists B, M2 acetylcholine 
receptor agonists, cholesteryl ester transfer protein inhibitors 
and for HIV infection treatment.20
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